Tezepelumab-ekko

(Tezspire)

Tezepelumab-ekko

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 210 mg/1.91 mL (110 mg/mL))
Drug ClassThymic stromal lymphopoietin blockers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

Product Monograph / Prescribing Information

Document TitleYearSource
Tezspire (tezepelumab-ekko) Prescribing Information.2023Amgen Inc., Thousand Oaks, CA and AstraZeneca AB, Sodertalje, Sweden

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Tezepelumab for treating severe asthma.2023NICE
Clinical, pharmacoeconomic, and stakeholder input combined report.2023CADTH
Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis.2023The Journal of Allergy and Clinical Immunology: In Practice
A comparison of the effectiveness of biologic therapies for asthma a systematic review and network meta-analysis.2023Annals of Allergy, Asthma & Immunology
Effects of tezepelumab on quality of life of patients with moderate-to-severe, uncontrolled asthma: systematic review and meta-analysis.2023Current Allergy and Asthma Reports
The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials.2023Medicine
Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials.2023American Journal of Respiratory and Critical Care Medicine
Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis.2022Journal of Asthma and Allergy
Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis. 2022Scientific Reports
Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis.2022Cells
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.2022Journal of Medical Economics
Tezepelumab for severe asthma.2021ICER
The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review.2021Biomedicines
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.2019Respiratory Research

Clinical Practice Guidelines

Document TitleYearSource
Asthma management in adults.2022The Journal of Allergy and Clinical Immunology: In Practice